Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;1481(1):43-58.
doi: 10.1111/nyas.14428. Epub 2020 Aug 6.

Potential proton pump inhibitor-related adverse effects

Issac E Perry  1 , Irene Sonu  2 , Carmelo Scarpignato  3   4 , Junichi Akiyama  5 , Michio Hongo  6   7 , Kenneth J Vega  1
Affiliations
Review

Potential proton pump inhibitor-related adverse effects

Issac E Perry et al. Ann N Y Acad Sci. 2020 Dec.

Erratum in

Abstract

Proton pump inhibitors (PPIs) are one of the most common medications taken by patients worldwide. PPIs are used to treat acid-related disorders, including gastroesophageal reflux disease, peptic ulcer disease, Helicobacter pylori infection, and nonsteroidal anti-inflammatory drug/stress ulceration. For some of these diseases, long-term treatment is necessary. With such prolonged use, concern and investigation into potential adverse effects has increased. In addition, data are available regarding potential anticancer effects of PPIs, especially regarding solid tumors. The aim of this review is to assess the literature on PPIs with regard to common concerns, such as drug-drug interactions, the intestinal microbiome, dementia and central nervous system disease, and osteoporosis, as well as to highlight potential negative and positive impacts of the drug in cancer.

Keywords: cancer; dementia; drug interactions; microbiota; osteoporosis; proton pump inhibitors.

PubMed Disclaimer

References

    1. Savarino, V., F. Di Mario & C. Scarpignato. 2009. Proton pump inhibitors in GORD. An overview of their pharmacology, efficacy and safety. Pharmacol. Res. 59: 135-153.
    1. Scarpignato, C., L. Gatta, A. Zullo, et al. 2016. Effective and safe proton pump inhibitor therapy in acid-related diseases - a position paper addressing benefits and potential harms of acid suppression. BMC Med. 14: 179.
    1. Vaezi, M.F., Y.X. Yang & C.W. Howden. 2017. Complications of proton pump inhibitor therapy. Gastroenterology 153: 35-48.
    1. Malfertheiner, P., A. Kandulski & M. Venerito. 2017. Proton-pump inhibitors: understanding the complications and risks. Nat. Rev. Gastroenterol. Hepatol. 14: 697-710.
    1. Elias, E. & L.E. Targownik. 2019. The clinician's guide to proton pump inhibitor related adverse events. Drugs 79: 715-731.

MeSH terms

Substances

LinkOut - more resources